GlassScriptPhysician profile
Richard P Thomas
NPI 1427406305
$5,185.02
in general payments reported to CMS, 2019-2025
33 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.24 · 2020: $29.01 · 2022: $665 · 2023: $1,147 · 2024: $1,571 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,350 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,350.15 |
| Education | $120.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $707.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $705.92 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $510.17 | 2022-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $491.66 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $440.31 | 2022-2025 | Ajovy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $274.26 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $269.36 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $250.85 | 2022-2025 | |
| Amgen INC. | $240.80 | 2022-2025 | Repatha, Otezla, Otezla |
| Xeris Pharmaceuticals, INC. | $120.47 | 2023-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $111.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $109.35 | 2022-2025 | Spravato |
| Lundbeck LLC | $95.26 | 2023-2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $92.16 | 2022-2024 | Quviviq |
| Dexcom, INC. | $89.44 | 2023-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $87.57 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $62.94 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $61.58 | 2024-2025 | Nexletol |
| Antares Pharma, INC. | $57.01 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.65 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Corcept Therapeutics | $49.48 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $44.86 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Indivior INC. | $36.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.11 | 2025 | Capvaxive, Gardasil 9, Vaxelis |
| Dynavax Technologies Corporation | $34.99 | 2023-2024 | Heplisav-B |
| Intuitive Surgical, INC. | $25.70 | 2024 | |
| Daiichi Sankyo INC. | $23.05 | 2024 | Injectafer |
| Astellas Pharma US INC | $20.74 | 2025 | Veozah |
| Cranial Technologies, INC | $20.69 | 2025 | Doc Band |
| Inspire Medical Systems, INC. | $19.61 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $16.61 | 2025 | Voquezna |
| Halozyme INC | $15.96 | 2023 | |
| Sanofi Pasteur INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.